Weekly Research Analysts’ Ratings Updates for Acer Therapeutics (ACER)

Several analysts have recently updated their ratings and price targets for Acer Therapeutics (NASDAQ: ACER):

  • 6/9/2021 – Acer Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.50 price target on the stock. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “
  • 6/8/2021 – Acer Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “
  • 6/2/2021 – Acer Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.25 price target on the stock. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “
  • 5/26/2021 – Acer Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.00 price target on the stock. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “
  • 5/24/2021 – Acer Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “
  • 5/18/2021 – Acer Therapeutics had its “market perform” rating reaffirmed by analysts at William Blair.
  • 5/18/2021 – Acer Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.00 price target on the stock. According to Zacks, “Acer Therapeutics Inc. is a pharmaceutical company. It develops therapies for the treatment of ultra-rare diseases with critical unmet medical need. The company’s product pipeline consists of Edsivo (TM) and ACER-001 which are in clinical stage. Acer Therapeutics Inc., formerly known as Opexa Therapeutics, Inc., is based in Cambridge, United States. “

Acer Therapeutics stock opened at $3.05 on Friday. Acer Therapeutics Inc. has a fifty-two week low of $2.15 and a fifty-two week high of $5.84. The stock has a market cap of $43.65 million, a P/E ratio of -1.82 and a beta of 1.49. The firm has a 50-day moving average price of $2.86.

Acer Therapeutics (NASDAQ:ACER) last issued its quarterly earnings results on Sunday, May 16th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.44) by $0.33. The company had revenue of $4.00 million during the quarter, compared to analyst estimates of $2.00 million. As a group, equities research analysts predict that Acer Therapeutics Inc. will post -1.12 earnings per share for the current year.

Hedge funds have recently modified their holdings of the stock. Virtu Financial LLC acquired a new position in Acer Therapeutics in the 1st quarter valued at about $55,000. Dimensional Fund Advisors LP acquired a new position in Acer Therapeutics in the 1st quarter valued at about $66,000. HighPoint Advisor Group LLC acquired a new position in Acer Therapeutics in the 4th quarter valued at about $113,000. Finally, Squarepoint Ops LLC acquired a new position in Acer Therapeutics in the 1st quarter valued at about $233,000. Hedge funds and other institutional investors own 11.44% of the company’s stock.

Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

Read More: Equal Weight Rating

Receive News & Ratings for Acer Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.